Shaken, not stirred: Mechanical stress testing of an IgG1 antibody

Journal of Pharmaceutical Sciences

Volumn 97, Issue 10, 2008, Pages 4347-4366

  Kiese, Sylvia ^a   Papppenberger, Astrid ^a   Friess, Wolfgang ^b   Mahler, Hanns Christian ^a  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

^b UNIVERSITY OF MUNICH   (Germany)

Author keywords

Dynamic light scattering; Fill volume; Light obscuration; Mechanical stress; Physical stability; Polysorbate; Protein aggregation; Shaking; Size exclusion chromatography; Stabilization; Stirring; Surfactants; Turbidity

Indexed keywords

IMMUNOGLOBULIN G1 ANTIBODY; MONOCLONAL ANTIBODY; POLYSORBATE;

ANALYTIC METHOD; ARTICLE; CONTROLLED STUDY; GEL PERMEATION CHROMATOGRAPHY; LIGHT SCATTERING; MECHANICAL STRESS; PARTICLE SIZE; PROTEIN AGGREGATION; PROTEIN STABILITY; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; TEMPERATURE; TURBIDITY;

EID: 55749109195     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.21328     Document Type: Article

References (56)

1. Pavlou AK, Belsey MJ. 2005. The therapeutic antibodies market to 2008. Eur J Pharm Biopharm 59:389-396.
2. Branden C, Tooze J. 1998. Introduction to protein structure, 2 edition, New York: Garland Science. p 410.
3. Rosenberg A. 2006. Effects of protein aggregates: An immunologic perspective, Volume 3. AAPS J 8:501-508.
4. Schellekens H. 2005. Factors influencing the immunogenicity of therapeutic proteins. Nephrol Dial Transplant 20:vi3-vi9.
5. Patten PA, Schellekens H. 2003. The immunogenicity of biopharmaceuticals. Lessons learned and consequences for protein drug development. Dev Biol (Basel) 112:81-97.
6. Lofgren JA, Wala I, Koren E, Swanson SJ, Jing S. 2006. Detection of neutralizing anti-therapeutic protein antibodies in serum or plasma samples containing high levels of the therapeutic protein. J Immunol Methods 308:101-108.
7. USP. 2006. USP/NF General Chapter 〈788〉 Particulate Matter in Injections, edition. United States Pharmacopeial Convention, Rockville, MO. Second Supplement.
8. Ph.Eur. 2007. 2.9. 19. Particulate contamination: Sub-visible particles. 5.8 edition. European Directorate for the Quality of Medicine (EDQM). pp. 253-255.
9. Ph.Eur. 2007. 2.9.20. Particulate contamination: Visible particles, 5.8 edition. European Directorate for the Quality of Medicine (EDQM). pp. 255-256.
10. Lumry R, Eyring H. 1954. Conformation changes of proteins. J Phys Chem 58:110-120.
11. Kendrick BS, Cleland JL, Lam X, Nguyen T, Randolph TW, Manning MC, Carpenter JF. 1998. Aggregation of recombinant human interferon gamma: Kinetics and structural transitions. J Pharm Sci 87:1069-1076.
12. Chi EY, Krishnan S, Randolph TW, Carpenter JF. 2003. Physical stability of proteins in aqueous solution: Mechanism and driving forces in nonnative protein aggregation. Pharm Res 20:1325-1336.
13. Murphy R, Amos T, editors. 2006. Misbehaving proteins: Protein (MIS) folding, aggregation, and stability. First edition. New York Inc: Springer-Verlag.
14. Mahler H-C, Muller R, Friess W, Delille A, Matheus S. 2005. Induction and analysis of aggregates in a liquid IgG1-antibody formulation. Eur J Pharm Biopharm 59:407-417.
15. Marcon G, Plakoutsi G, Chiti F. 2006. Protein aggregation starting from the native globular state, methods in enzymology. In: Wetzel IKAR, editor. Amyloid, Prions, and Other Protein Aggregates, Part C, Volume 413 edition. Burlington, MA: Academic Press. pp. 75-91.
16. Uversky VN. 2005. A GLYmmer of Insight into Fibril Formation. Structure 13:1090-1092.
17. Cleland JL, Powell MF, Shire SJ. 1993. The development of stable protein formulations: A close look at protein aggregation, deamidation, and oxidation. Crit Rev Ther Drug Carrier Syst 10:307-377.
18. Philo JS. 2006. Is any measurement method optimal for all aggregate sizes and types? Volume 3. AAPS J 8:E564-E571.
19. Carpenter JF, Kendrick BS, Chang BS, Manning MC, Randolph TW. 1999. Inhibition of stress-induced aggregation of protein therapeutics. Methods Enzymol 309:236-255.
20. Wang W. 1999. Instability, stabilization, and formulation of liquid protein pharmaceuticals. Int J Pharm 185:129-188.
21. Mahler H-C, Friess W, Grauschopf U, Kiese S. 2008. Protein aggregation: Pathways, induction factors and analysis. J Pharm Sci (submitted).
22. Virkar PD, Narendranathan TJ, Hoare M, Dunnill P. 1981. Studies of the effect of shear on globular proteins: Extension to high shear fields and to pumps. Biotechnol Bioeng 23:425-429.
23. Maa Y-F, Hsu CC. 1996. Effect of high shear on proteins. Biotechnol Bioeng 51:458-465.
24. Colombie S, Gaunand A, Lindet B. 2001. Lysozyme inactivation under mechanical stirring: Effect of physical and molecular interfaces. Enzyme Microb Technol 28:820-826.
25. Maa Y-F, Hsu CC. 1997. Protein denaturation by combined effect of shear and air-liquid interface. Biotechnol Bioeng 54:503-512.
26. Wang W, Wang YJ, Wang D. 2007. Dual effects of Tween 80 on protein stability. Int J Pharm 347:31-38.
27. Wang W, Wang YJ, Wang DQ. 2008. Dual effects of Tween 80 on protein stability. Int J Pharm 347:31-38.
28. Capelle MAH, Gurny R, Arvinte T. 2007. High throughput screening of protein formulation stability: Practical considerations. Eur J Pharm Biopharm 65:131-148.
29. Bam NB, Cleland JL, Yang J, Manning MC, Carpenter JF, Kelley RF, Randolph TW. 1998. Tween protects recombinant human growth hormone against agitation-induced damage via hydrophobic interactions. J Pharm Sci 87:1554-1559.
30. Chang BS, Kendrick BS, Carpenter JF. 1996. Surface-induced denaturation of proteins during freezing and its inhibition by surfactants. J Pharm Sci 85:1325-1330.
31. Bam NB, Randolph TW, Cleland JL. 1995. Stability of protein formulations: Investigation of surfactant effects by a novel EPR spectroscopic technique. Pharm Res 12:2-11.
32. Mahler H-C, Printz M, Kopf R, Schuller R, Müller R. 2007. Behaviour of polysorbate 20 during dialysis, concentration and filtration using membrane separation techniques. J Pharm Sci 97:982-992.
33. Kerker M. 1987. Classics and classicists of colloid and interface science: John Tyndall. J Colloid Interface Sci 119:602-604.
34. Ph.Eur. 2007. 2.21. Clarity and degree of opalescense of liquids, 5.8 edition. European Directorate for the Quality of Medicine (EDQM). pp. 23-23.
35. Ionescu RM, Vlasak J, Price C, Kirchmeier M. 2007. Contribution of variable domains to the stability of humanized IgG1 monoclonal antibodies. J Pharm Sci (article online in advance of print).
36. Henson AF, Mitchell JR, Mussellwhite PR. 1970. The surface coagulation of proteins during shaking. J Colloid Interface Sci 32:162-165.
37. Charman SA, Mason KL, Charman WN. 1993. Techniques for assessing the effects of pharmaceutical excipients on the aggregation of porcine growth hormone. Pharm Res 10:954-962.
38. Wang W, Singh S, Zeng DL, King K, Nema S. 2007. Antibody structure, instability, and formulation. J Pharm Sci 96:1-26.
39. Baszkin A, Boissonnade MM, Kamyshny A, Magdassi S. 2001. Native and hydrophobically modified human immunoglobulin G at the air/water interface: Sequential and competitive adsorption. J Colloid Interface Sci 239:1-9.
40. Chang S-H, Chen L-Y, Chen W-Y. 2005. The effects of denaturants on protein conformation and behavior at air/solution interface. Colloids Surf B Biointerfaces 41:1-6.
41. Donaldson TL, Boonstra EF, Hammond JM. 1980. Kinetics of protein denaturation at gas-liquid interfaces. J Colloid Interface Sci 74:441-450.
42. Thomas CR, Nienow AW, Dunnill P. 1979. Action of shear on enzymes: Studies with alcohol dehydrogenase. Biotechnol Bioeng 21:2263-2278.
43. Charm SE, Wong BL. 1981. Shear effects on enzymes. Enzyme Microb Technol 3:111-118.
44. Santos O, Nylander T, Paulsson M, Tragardh C. 2006. Whey protein adsorption onto steel surfaces-effect of temperature, flow rate, residence time and aggregation. J Food Eng 74:468-483.
45. Gulseren I, Guzey D, Bruce BD, Weiss J. 2007. Structural and functional changes in ultrasonicated bovine serum albumin solutions. Ultrason Sonochem 14:173-183.
46. Bernstein LS, Zakin MR, Flint EB, Suslick KS. 1996. Cavitation thermometry using molecular and continuum sonoluminescence. J Phys Chem 100:6612-6619.
47. Morel M-H, Redl A, Guilbert S. 2002. Mechanism of heat and shear mediated aggregation of wheat gluten protein upon mixing. Biomacromolecules 3:488-497.
48. Eckhardt BM, Oeswein JQ, Yeung DA, Milby TD, Bewley TA. 1994. A turbidimetric method to determine visual appearance of protein solutions. J Pharm Sci Technol Off J PDA 48:64-70.
49. Kim D, Lee YJ, Corry PM. 1992. Employment of a turbidimetric assay system to measure heat-induced protein aggregation. J Therm Biol 17:297-303.
50. Katakam M, Bell LN, Banga AK. 1995. Effect of surfactants on the physical stability of recombinant human growth hormone. J Pharm Sci 84:713-716.
51. Kreilgaard L, Jones LS, Randolph TW, Frokjaer S, Flink JM, Manning MC, Carpenter JF. 1998. Effect of Tween 20 on freeze-thawing- and agitation-induced aggregation of recombinant human factor XIII. J Pharm Sci 87:1597-1603.
52. Mueller R, Mahler H-C, Senner F, Maeder K. 2007. Pharmaceutical Science World Conference EAPB and EUFEPS Workshop on Monoclonal Antibodies Poster presentation, April 26-27 2007, Amsterdam, The Netherlands.
53. Tzannis ST, Hrushesky WJM, Wood PA, Przybycien TM. 1997. Adsorption of a formulated protein on a drug delivery device surface. J Colloid Interface Sci 189:216-228.
54. Chi EY, Weickmann J, Carpenter JF, Manning MC, Randolph TW. 2005. Heterogeneous nucleation-controlled particulate formation of recombinant human platelet-activating factor acetylhydrolase in pharmaceutical formulation. J Pharm Sci 94:256-274.
55. Demeule B, Lawrence MJ, Drake AF, Gurny R, Arvinte T. 2007. Characterization of protein aggregation: The case of a therapeutic immunoglobulin. Biochim Biophys Acta (BBA) Proteins Proteomics 1774:146-153.
56. Gabrielson JP, Brader M L, Pekar AH, Mathis KB, Winter G, Carpenter JF, Randolph TW. 2007. Quantitation of aggregate levels in a recombinant humanized monoclonal antibody formulation by size-exclusion chromatography, asymmetrical flow field flow fractionation, and sedimentation velocity.